Deals3 Apr 2025, 05:36 pm
Medicamen Biotech Inks CDMO Contract with XGX Pharma for 6 Products
AI Summary
Medicamen Biotech Ltd. has announced that it has signed a contract with XGX Pharma, a European company, for Contract Development and Manufacturing Services (CDMO). Under this agreement, Medicamen will be responsible for developing 6 products and manufacturing them for XGX Pharma. The market authorisation will be held by XGX Pharma. This is a significant step for Medicamen in expanding its CDMO business and strengthening its presence in the European market.
Key Highlights
- Medicamen Biotech has signed a CDMO contract with XGX Pharma
- The contract involves the development and manufacturing of 6 products
- XGX Pharma will hold the market authorisation
- This is a strategic move by Medicamen to expand its CDMO business
- The deal strengthens Medicamen's presence in the European market